Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study

Frontiers in Pharmacology

Volumn 8, Issue JUN, 2017, Pages

  Colafrancesco, Serena ^a   Priori, Roberta ^a   Valesini, Guido ^a   Argolini, Lorenza ^b   Baldissera, Elena ^c   Bartoloni, Elena ^d   Cammelli, Daniele ^e,f   Canestrari, Giovanni ^g   Cantarini, Luca ^h   Cavallaro, Elena ⁱ   Cavalli, Giulio ^c,j   Cerrito, Lucia ^k   Cipriani, Paola ^l   Dagna, Lorenzo ^c,j   De Marchi, Ginevra ⁱ   De Vita, Salvatore ⁱ   Emmi, Giacomo ^e   Ferraccioli, Gianfranco ^g   Frassi, Micol ^m   Galeazzi, Mauro ^h   Gerli, Roberto ^d   Giacomelli, Roberto ^l   Gremese, Elisa ^g   Iannone, Florenzo ⁿ   Lapadula, Giovanni ⁿ   Lopalco, Giuseppe ⁿ   Manna, Raffaele ^k   Mathieu, Alessandro ^o   Montecucco, Carlomaurizio ^p   Mosca, Marta ^q   Piazza, Ilaria ^r   Piga, Matteo ^o   Pontikaki, Irene ^b   Romano, Micol ^b   Rossi, Silvia ^p   Rossini, Maurizio ^r   Ruscitti, Piero ^l   Silvestri, Elena ^e   Stagnaro, Chiara ^q   Talarico, Rosaria ^q   Tincani, Angela ^m   Viapiana, Ombretta ^r   Vitiello, Gianfranco ^f   Fabris, Francesca ^s   Bindoli, Sara ^s   Punzi, Leonardo ^s   Galozzi, Paola ^s   Sfriso, Paolo ^s   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Dept of Internal Medicine   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^k FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^l UNIVERSITY OF L'AQUILA   (Italy)

^m UNIVERSITY OF BRESCIA   (Italy)

ⁿ UNIVERSITY OF BARI   (Italy)

^o DEPARTMENT OF RADIOLOGY   (Italy)

^p UNIVERSITY OF PAVIA   (Italy)

^q UNIVERSITY OF PISA   (Italy)

^r UNIVERSITY OF VERONA   (Italy)

^s UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

Adult onset Still's disease; Anakinra; Canakinumab; Interleukin (IL) 1; Treatment

Indexed keywords

ANAKINRA; CANAKINUMAB;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; ITALIAN (CITIZEN); LEUKOPENIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PNEUMONIA; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTE COUNT; TOOTH ABSCESS; URINARY TRACT INFECTION;

EID: 85020797590     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00369     Document Type: Article

References (34)

1. Barsotti, S., Neri, R., Iacopetti, V., d'Ascanio, A., Talarico, R., Tripoli, A., et al. (2014). Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J. Clin. Rheumatol. 20, 121. doi: 10.1097/RHU.0000000000000082
2. Cavalli, G., Franchini, S., Aiello, P., Guglielmi, B., Berti, A., Campochiaro, C., et al. (2015). Efficacy and safety of biological agents in adult-onset Still's disease. Scand. J. Rheumatol. 44, 309-314. doi: 10.3109/03009742.2014.992949
3. Cefle, A. (2005). Leflunomide and azathioprine combination in refractory adult-onset Still's disease. Ann. Pharmacother. 39, 764-767. doi: 10.1345/aph.1E425
4. Colafrancesco, S., Priori, R., Alessandri, C., Perricone, C., Pendolino, M., Picarelli, G., et al. (2012). IL-18 serum level in adult onset Still's disease: a marker of disease activity. Int. J. Inflamm. 2012:156890. doi: 10.1155/2012/156890
5. Colafrancesco, S., Priori, R., and Valesini, G. (2015). Presentation and diagnosis of adult-onset Still's disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev. Clin. Immunol. 11, 749-761. doi: 10.1586/1744666X.2015.1037287
6. Dinarello, C. A. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732. doi: 10.1182/blood-2010-07-273417
7. Fautrel, B., Sibilia, J., Mariette, X., Combe, B., and Club Rhumatismes et Inflammation (2005). Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann. Rheum. Dis. 64, 262-266. doi: 10.1136/ard.2004.024026
8. Fujii, T., Nojima, T., Yasuoka, H., Satoh, S., Nakamura, K., Kuwana, M., et al. (2001). Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology 40, 1398-1404
9. Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., and Sève, P. (2014a). Adult-onset Still's disease. Autoimmun. Rev. 13, 708-722. doi: 10.1016/j.autrev.2014.01.058
10. Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., Iwaz, J., Ninet, J., Durieu, I., et al. (2014b). Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine 93, 91-99. doi: 10.1097/MD.0000000000000021
11. Giampietro, C., and Fautrel, B. (2012). Anti-interleukin-1 agents in adult onset Still's disease. Int. J. Inflamm. 2012:317820. doi: 10.1155/2012/317820
12. Giampietro, C., Ridene, M., Lequerré, T., Costedoat Chalumeau, N., Amoura, Z., Sellam, J., et al. (2013). Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 65, 822-826. doi: 10.1002/acr.21901
13. Hong, D., Yang, Z., Han, S., Liang, X., Ma, K., and Zhang, X. (2014). Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des. Dev. Ther. 8, 2345-2357. doi: 10.2147/DDDT.S73428
14. Jamilloux, Y., Gerfaud-Valentin, M., Henry, T., and Sève, P. (2015). Treatment of adult-onset Still's disease: a review. Ther. Clin. Risk Manag. 11, 33-43. doi: 10.2147/TCRM.S64951
15. Kim, H. A., Sung, J. M., and Suh, C. H. (2012). Therapeutic responses and prognosis in adult-onset Still's disease. Rheumatol. Int. 32, 1291-1298. doi: 10.1007/s00296-011-1801-6
16. Kontzias, A., and Efthimiou, P. (2012). The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin. Arthritis Rheum. 42, 201-205. doi: 10.1016/j.semarthrit.2012.03.004
17. Kötter, I., Wacker, A., Koch, S., Henes, J., Richter, C., Engel, A., et al. (2007). Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin. Arthritis Rheum. 37, 189-197. doi: 10.1016/j.semarthrit.2007.04.002
18. Laskari, K., Tzioufas, A. G., and Moutsopoulos, H. M. (2011). Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res. Ther. 13, R91. doi: 10.1186/ar3366
19. Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. (2008). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302-308. doi: 10.1136/ard.2007.076034
20. Lo Gullo, A., Caruso, A., Pipitone, N., Macchioni, P., Pazzola, G., and Salvarani, C. (2014). Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations. Joint Bone Spine 81, 376-377. doi: 10.1016/j.jbspin.2013.12.011
21. Maria, A. T., Le Quellec, A., Jorgensen, C., Touitou, I., Rivière, S., and Guilpain, P. (2014). Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun. Rev. 13, 1149-1159. doi: 10.1016/j.autrev.2014.08.032
22. Nirmala, N., Brachat, A., Feist, E., Blank, N., Specker, C., Witt, M., et al. (2015). Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr. Rheumatol. Online J. 13, 50. doi: 10.1186/s12969-015-0047-3
23. Nordström, D., Knight, A., Luukkainen, R., van Vollenhoven, R., Rantalaiho, V., Kajalainen, A., et al. (2012). Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J. Rheumatol. 39, 2008-2011
24. Ortiz-Sanjuán, F., Blanco, R., Riancho-Zarrabeitia, L., Castañeda, S., Olivé, A., Riveros, A., et al. (2015). Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. Medicine 94:e1554. doi: 10.1097/MD.0000000000001554
25. Priori, R., Ceccarelli, F., Barone, F., Iagnocco, A., and Valesini, G. (2008). Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease. Clin. Exp. Rheumatol. 26, 933-937
26. Priori, R., Colafrancesco, S., Alessandri, C., Minniti, A., Perricone, C., Iaiani, G., et al. (2014). Interleukin 18: a biomarker for differential diagnosis between adult-onset Still's disease and sepsis. J. Rheumatol. 41, 1118-1123. doi: 10.3899/jrheum.130575
27. Rau, M., Schiller, M., Krienke, S., Heyder, P., Lorenz, H., and Blank, N. (2010). Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J. Rheumatol. 37, 2369-2376. doi: 10.3899/jrheum.100247
28. Rossi-Semerano, L., Fautrel, B., Wendling, D., Hachulla, E., Galeotti, C., Semerano, L., et al. (2015). Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J. Rare Dis. 10, 19. doi: 10.1186/s13023-015-0228-7
29. Rudinskaya, A., and Trock, D. H. (2003). Successful treatment of a patient with refractory adult-onset still disease with anakinra. J. Clin. Rheumatol. 9, 330-332. doi: 10.1097/01.rhu.0000089966.48691.7f
30. Ruscitti, P., Cipriani, P., Masedu, F., Iacono, D., Ciccia, F., Liakouli, V., et al. (2016). Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 14:194. doi: 10.1186/s12916-016-0738-8
31. Sfriso, P., Priori, R., Valesini, G., Rossi, S., Montecucco, C. M., D'Ascanio, A., et al. (2016). Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin. Rheumatol. 35, 1683-1689. doi: 10.1007/s10067-016-3308-8
32. Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., et al. (2016). A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front. Pharmacol. 7:380. doi: 10.3389/fphar.2016.00380
33. Weber, A., Wasiliew, P., and Kracht, M. (2010). Interleukin-1 (IL-1) pathway. Sci. Signal. 3:cm1. doi: 10.1126/scisignal.3105cm1
34. Yamaguchi, M., Ohta, A., Tsunematsu, T., Kasukawa, R., Mizushima, Y., Kashiwagi, H., et al. (1992). Preliminary criteria for classification of adult Still's disease. J. Rheumatol. 19, 424-430